MAB: Multisensory Augmentation for Post-stroke Standing Balance

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT05760885
Collaborator
(none)
36
1
2
27
1.3

Study Details

Study Description

Brief Summary

Many individuals who experience a stroke have problems with their balance. In part, these balance problems may be due to sensory issues. This study will test whether sensory augmentation has the potential to improve post-stroke balance. Sensory augmentation is a method by which non-invasive vibration is used to enhance the sensory information available to users, which may make it easier to feel where they are and prevent losses of balance.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Balance training with sensory augmentation
  • Behavioral: Balance training
Early Phase 1

Detailed Description

The objective of this study is to design a novel multisensory augmentation approach to improve the control of standing balance in people with chronic stroke. With sensory augmentation, artificial feedback provides the nervous system with information about the dynamic state of the body, which can be used to prevent losses of balance. This clinical trial will investigate whether multisensory augmentation produces sustained balance improvements when applied as a training device. These potential improvements will be assessed by comparing the results of clinical and biomechanical assessments before and after a 10-week balance training program, in which half of the participants will be randomly assigned sensory augmentation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomly assigned to either a Control or an Experimental group. The Experimental group will receive sensory augmentation during balance training, while the Control group will not.Participants will be randomly assigned to either a Control or an Experimental group. The Experimental group will receive sensory augmentation during balance training, while the Control group will not.
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcomes assessors will not be informed of which group participants are assigned to, and will not be present during an training sessions. As participants will be aware whether or not they will receive sensory augmentation (in the form of vibration), they can not be masked.
Primary Purpose:
Treatment
Official Title:
Multisensory Augmentation to Improve the Standing Balance of People With Chronic Stroke
Anticipated Study Start Date :
Oct 1, 2024
Anticipated Primary Completion Date :
Jan 1, 2027
Anticipated Study Completion Date :
Jan 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sensory Augmentation

Participants will receive sensory augmentation in the form of non-invasive vibration, while balance training is performed as described below.

Behavioral: Balance training with sensory augmentation
Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.

Active Comparator: Control

Participants will receive balance training, without any sensory augmentation.

Behavioral: Balance training
Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.

Outcome Measures

Primary Outcome Measures

  1. Berg Balance Scale score change [Before and after a 10-week period of balance training]

    A standard clinical assessment to measure balance performance during various functional tasks

Secondary Outcome Measures

  1. Limits of Stability score (paretic direction) [Before and after a 10-week period of balance training]

    A standard assessment of how far participants are willing and able to shift their weight toward the paretic leg while standing

  2. Limits of Stability score (non-paretic direction) [Before and after a 10-week period of balance training]

    A standard assessment of how far participants are willing and able to shift their weight toward the non-paretic leg while standing

  3. Mediolateral center of pressure velocity [Before and after a 10-week period of balance training]

    A measure of sideways sway, which will be quantified as participants stand on a platform that translates sideways, challenging participant balance

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age of at least 21 years;

  2. Experience of a stroke at least 6 months prior to participation;

  3. Berg Balance Scale score less than 52

  4. Ability to stand independently for at least 1 minute without wearing an AFO or other brace that would preclude delivery of stimulation to the ankle or foot sole

  5. Provision of informed consent

Exclusion Criteria:
  1. Resting blood pressure higher than 220/110 mm Hg

  2. History of unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living

  3. Pre-existing neurological disorders or dementia

  4. Severe visual impairment

  5. History of DVT or pulmonary embolism within 6 months

  6. Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ralph H. Johnson VA Medical Center, Charleston, SC Charleston South Carolina United States 29401-5703

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Jesse C. Dean, PhD, Ralph H. Johnson VA Medical Center, Charleston, SC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT05760885
Other Study ID Numbers:
  • A4545-R
  • I01 RX004545
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2023